Business Description
Cogent Biosciences is a clinical-stage company working to develop targeted treatments for patients with specific genetic mutations that drive serious diseases. Its most advanced drug, bezuclastinib, is currently in Phase 3 testing and aims to treat conditions such as systemic mastocytosis and certain gastrointestinal tumors by blocking the faulty protein signals that cause them. The company also has several earlier-stage drugs in development targeting other genetic abnormalities found in cancers including bile duct cancer and solid tumors. Based in Waltham, Massachusetts, Cogent operates under a licensing agreement with Plexxikon Inc. covering the development and commercialization of its lead treatment.
